Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

Ajanta Pharma Limited's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 2.926000
forwardPE 28.216915
debtToEquity 5.698000
earningsGrowth 0.206000
revenueGrowth 0.141000
grossMargins 0.757480
operatingMargins 0.240680
trailingEps 77.980000
forwardEps 96.335830

With a current ratio of 2.926, AJANTPHARM has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that AJANTPHARM is in a strong position to meet its immediate financial obligations without difficulty.
AJANTPHARM's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
AJANTPHARM's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods.
AJANTPHARM's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
AJANTPHARM's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in AJANTPHARM's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

Price projections for AJANTPHARM have consistently been revised upward, indicating positive sentiment toward the company. This gradual adjustment reflects growing confidence in AJANTPHARM's future potential and financial outlook among analysts.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


In recent market activity, 8 sales of Ajanta Pharma Limited shares took place, with market price at 2733.9437561035156.There were no sell transactions throughout the period under consideration.The higher volume of buys compared to sells near current AJANTPHARM price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


With analysts showing a buy bias for AJANTPHARM, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning AJANTPHARM as a safe and profitable place for investors to allocate their funds and seek growth.